ABSTRACT
OBJECTIVE: To investigate the changes of platelet mitochondrial adenosine triphosphate synthase 6( ATPase-6)gene in patients with occupational chronic myeloid leukemia( CML) caused by benzene. METHODS: Five occupational benzene induced CML patients were selected as the case group and 21 healthy workers without benzene exposure were selected as the control group,venous blood were drew from these study subjects. The number of platelet was counted. The level of mitochondrial ATPase-6 gene was examined by quantitative polymerase chain reaction. RESULTS: The platelet count in case group was lower than that of control group [( 135. 2 ± 32. 6) ×10~9/ L vs( 239. 7 ± 77. 5) ×10~9/ L,P < 0. 05]. The ratio of ATPase-6 gene / platelet was higher than that of control group( median: 3. 43 ×10~(-4)copies vs 1. 87 ×10~(-4)copies,P < 0. 05). The ATPase-6 gene level in case group showed no significant difference when compared with that of control group( median: 4. 83 ×10~7 copies / L vs 3. 24 ×10~7 copies / L,P > 0. 05). CONCLUSION: The benzene induced CML patients shows more sensitive change in ratio of ATPase-6 gene / platelet than in ATPase-6 gene level.
ABSTRACT
Abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) are the major cause of in-stent restenosis (ISR). Intervention proliferation and migration of VSMCs is an important strategy for antirestenotic therapy. Roscovitine, a second-generation cyclin-dependent kinase inhibitor, can inhibit cell cycle of multiple cell types. We studied the effects of roscovitine on cell cycle distribution, proliferation and migration of VSMCs in vitro by flow cytometry, BrdU incorporation and wound healing assay, respectively. Our results showed that roscovitine increased the proportion of G0/G1 phase cells after 12 h (69.57±3.65 vs. 92.50±1.68, P=0.000), 24 h (80.87±2.24 vs. 90.25±0.79, P=0.000) and 48 h (88.08±3.86 vs. 88.87±2.43, P=0.427) as compared with control group. Roscovitine inhibited proliferation and migration of VSMCs in a concentration-dependent way. With the increase of concentration, roscovitine showed increased capacity for growth and migration inhibition. Roscovitine (30 μmol/L) led to an almost complete VSMCs growth and migration arrest. Combined with its low toxicity and selective inhibition to ISR-VSMCs, roscovitine may be a potential drug in the treatment of vascular stenosis diseases and particularly useful in the prevention and treatment of ISR.
ABSTRACT
Abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) are the major cause of in-stent restenosis (ISR). Intervention proliferation and migration of VSMCs is an important strategy for antirestenotic therapy. Roscovitine, a second-generation cyclin-dependent kinase inhibitor, can inhibit cell cycle of multiple cell types. We studied the effects of roscovitine on cell cycle distribution, proliferation and migration of VSMCs in vitro by flow cytometry, BrdU incorporation and wound healing assay, respectively. Our results showed that roscovitine increased the proportion of G0/G1 phase cells after 12 h (69.57±3.65 vs. 92.50±1.68, P=0.000), 24 h (80.87±2.24 vs. 90.25±0.79, P=0.000) and 48 h (88.08±3.86 vs. 88.87±2.43, P=0.427) as compared with control group. Roscovitine inhibited proliferation and migration of VSMCs in a concentration-dependent way. With the increase of concentration, roscovitine showed increased capacity for growth and migration inhibition. Roscovitine (30 μmol/L) led to an almost complete VSMCs growth and migration arrest. Combined with its low toxicity and selective inhibition to ISR-VSMCs, roscovitine may be a potential drug in the treatment of vascular stenosis diseases and particularly useful in the prevention and treatment of ISR.
Subject(s)
Animals , Rats , Cell Cycle , Cell Line , Cell Movement , Graft Occlusion, Vascular , Drug Therapy , Metabolism , Pathology , Muscle, Smooth, Vascular , Metabolism , Pathology , Myocytes, Smooth Muscle , Metabolism , Pathology , Protein Kinase Inhibitors , Pharmacology , Purines , PharmacologyABSTRACT
<p><b>OBJECTIVE</b>To analyze the correlation between olfactory bulb (OB) volume with depth of olfactory sulcus (OS) and olfactory function in patients with idiopathic rapid eye movement sleep behavior disorder (iRBD).</p><p><b>METHODS</b>Fifty patients with iRBD and fifty controls were assessed with polysomnography (PSG). The results of olfactory function T & T testing, OB volume and depth of OS assessed with magnetic resonance imaging (MRI) were compared. SPSS 11.0 software was used to analyze the data.</p><p><b>RESULTS</b>T & T olfactory testing revealed that iRBD patients had higher scores (3.1 ± 0.5) than those in controls (0.6 ± 0.1), and the difference was significant (t = 7.913, P < 0.05). Both men and women with iRBD were affected by the same extent of olfactory loss (t = 1.015, P > 0.05). OB volume of left side in iRBD patients was (33.75 ± 4.11) mm(3), right side was (34.57 ± 4.21) mm(3), average OB volume was (33.94 ± 4.15) mm(3); OB volume of left side in controls was (51.68 ± 7.71) mm(3), right side was (52.31 ± 7.77) mm(3), average OB volume was (51.94 ± 7.74) mm(3); OB volume were lower in iRBD patients as compared to controls (t value were 9.013, 8.889 and 8.923, all P < 0.01). OS depth study revealed no statistical difference between iRBD patients and controls (t value were 0.923, 0.897 and 0.904, all P > 0.05). Olfactory discriminate threshold was negatively correlated with OB volume in iRBD patients (r = -0.61, P < 0.05), but no correlated with depth of OS (r = -0.24, P > 0.05).</p><p><b>CONCLUSIONS</b>The OB volume was lower in iRBD patients as compared to controls. The depth of OS showed no significant changes in iRBD patients. The OB volume was correlated with olfactory function, while the depth of OS was no correlated with olfactory function.</p>